中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1917-1925

Expression of splicing factor 3B subunit 6 in pancreatic cancer and its effect on the biological behaviors of pancreatic cancer cells

DOI: 10.12449/JCH260825

  • Department of Hepatobiliary Surgery，Binzhou Medical University Hospital，Binzhou，Shandong 256603，China

Research funding:

Shandong Provincial Clinical Key Specialty Construction Project (SLCZDZK-0701)

More Information
  • Corresponding author: Zhang Xingyuan， byfyzxy@163.com （ORCID： 0000-0002-7405-3805）
  • Received Date: 2026-03-14
  • Accepted Date: 2026-04-02
  • Published Date: 2026-08-25
    Abstract
  •   Objective  To systematically clarify the expression profile of splicing factor 3B subunit 6 （SF3B6） in pancreatic cancer， its clinical prognostic value， and its regulatory effect on the malignant phenotype of cancer cells through bioinformatics analysis， clinical sample validation， and in vitro functional experiments， and to assess its potential as a novel tumor biomarker.  Methods  Transcriptomic and clinical data were downloaded from The Cancer Genome Atlas and Xena public databases at The University of California Santa Cruz to investigate the difference in the expression of SF3B6 between pancreatic cancer tissue and normal pancreatic tissue， and the association of SF3B6 with the prognosis and clinical indices of patients with pancreatic cancer was analyzed. Three pancreatic ductal adenocarcinoma cell lines and one normal pancreatic ductal epithelial cell line were cultured， and RT-qPCR was used to measure the expression level of SF3B6 in pancreatic cancer. A total of 43 patients with pancreatic cancer who underwent surgery in Binzhou Medical University Hospitalfrom January 2024 to December 2025 were enrolled as subjects， and Western blot and RT-qPCR were used to measure the expression of SF3B6 in pancreatic cancer tissue. Based on the median expression level of SF3B6 measured by RT-qPCR， the patients were divided into high and low expression groups. The association of SF3B6 expression with clinical features and prognosis was assessed. A pancreatic cancer cell line with stable low SF3B6 expression was constructed， and CCK-8 assay and Transwell migration and invasion assays were used to observe the impact of SF3B6 on the biological behaviors of the pancreatic cancer cell line， including proliferation， migration， and invasion. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and a one-way analysis of variance was used for comparison between multiple groups， while the least significant difference t-test or the Games-Howell test was used for further comparison between two groups； the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data between two groups. The chi-square test was used for comparison of categorical data between two groups. A Logistic regression analysis was used to investigate the influencing factors for the expression of SF3B6， and the univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate the risk factors for prognosis.  Results  The bioinformatics analysis showed that SF3B6 was highly expressed in pancreatic cancer tissue （P<2.2×10-16） and significantly affected the overall survival （P=0.011） and progression-free survival （P=0.002） of patients with pancreatic cancer. Sex， age， clinical stage， and TNM stage were not influencing factors for SF3B6 expression （all P>0.05）， and SF3B6 could be used as an independent risk factor for the survival outcome of patients with pancreatic cancer （overall survival： hazard ratio=2.26， 95% confidence interval： 1.13 — 4.50， P=0.021； progression-free survival： hazard ratio=2.37，95% confidence interval： 1.22 — 4.58， P=0.010）. Cellular and tissue experiments confirmed the high expression level of SF3B6 in pancreatic cancer cell lines （P<0.05）， and the expression level of SF3B6 increased with the increase in the malignancy of pancreatic cancer， showing the highest relative expression level in PANC-1 cells with the highest degree of malignancy； the expression level of SF3B6 in the solid tissue of pancreatic cancer was significantly higher than that in paracancerous tissue （P<0.01）. The expression level of SF3B6 might affect the overall survival of patients with pancreatic cancer （P<0.05）， while it showed no significant association with age， sex， pathological grade， maximum tumor diameter， or clinical stage （all P>0.05）. Knockdown of SF3B6 significantly inhibited the proliferation， migration， and invasion of pancreatic cancer cells （all P<0.01）.  Conclusion  SF3B6 is highly expressed in pancreatic cancer， and the high expression of SF3B6 can promote the proliferation， migration， and invasion of pancreatic cancer cells. Therefore， SF3B6 can be used as a potential biomarker for prognostic evaluation.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    Farhangnia P, Khorramdelazad H, Nickho H, et al. Current and future immunotherapeutic approaches in pancreatic cancer treatment[J]. J Hematol Oncol, 2024, 17( 1): 40. DOI: 10.1186/s13045-024-01561-6.
    [2]
    Du Nan, Wei Miaoyan, Xu Jin. Advancements and frontiers in targeted therapy for pancreatic cancer[J]. Chin J Clin Pharmacol Ther, 2025, 30( 2): 183- 192. DOI: 10.12092/j.issn.1009-2501.2025.02.004.

    杜楠, 魏妙艳, 徐近. 胰腺癌的靶向治疗进展及前沿[J]. 中国临床药理学与治疗学, 2025, 30( 2): 183- 192. DOI: 10.12092/j.issn.1009-2501.2025.02.004.
    [3]
    Liu Yueze, Zhang Taiping, Zhao Yupei. Advances and thoughts in the diagnosis and treatment of pancreatic cancer[J]. J Clin Hepatol, 2025, 41( 4): 601- 604. DOI: 10.12449/JCH250401.

    刘悦泽, 张太平, 赵玉沛. 胰腺癌诊治的进展与思考[J]. 临床肝胆病杂志, 2025, 41( 4): 601- 604. DOI: 10.12449/JCH250401.
    [4]
    Angarola B L, Anczuków O. Splicing alterations in healthy aging and disease[J]. Wiley Interdiscip Rev RNA, 2021, 12( 4): e1643. DOI: 10.1002/wrna.1643.
    [5]
    Stanley R F, Abdel-Wahab O. Dysregulation and therapeutic targeting of RNA splicing in cancer[J]. Nat Cancer, 2022, 3( 5): 536- 546. DOI: 10.1038/s43018-022-00384-z.
    [6]
    Alors-Pérez E, Pedraza-Arevalo S, Blázquez-Encinas R, et al. Splicing alterations in pancreatic ductal adenocarcinoma: A new molecular landscape with translational potential[J]. J Exp Clin Cancer Res, 2023, 42( 1): 282. DOI: 10.1186/s13046-023-02858-z.
    [7]
    van der Feltz C, Hoskins A A. Structural and functional modularity of the U2 snRNP in pre-mRNA splicing[J]. Crit Rev Biochem Mol Biol, 2019, 54( 5): 443- 465. DOI: 10.1080/10409238.2019.1691497.
    [8]
    Sun C F. The SF3b complex: Splicing and beyond[J]. Cell Mol Life Sci, 2020, 77( 18): 3583- 3595. DOI: 10.1007/s00018-020-03493-z.
    [9]
    Stoop T F, Javed A A, Oba A, et al. Pancreatic cancer[J]. Lancet, 2025, 405( 10485): 1182- 1202. DOI: 10.1016/S0140-6736(25)00261-2.
    [10]
    Zhang Taiping, Ye Liyuan, Wang Yuanyang. Development and practice of precise treatment of pancreatic cancer[J]. Chin J Dig Surg, 2025, 24( 5): 567- 573. DOI: 10.3760/cma.j.cn115610-20250411-00147.

    张太平, 叶力源, 王苑阳. 胰腺癌精准治疗的发展与实践[J]. 中华消化外科杂志, 2025, 24( 5): 567- 573. DOI: 10.3760/cma.j.cn115610-20250411-00147.
    [11]
    Rahib L, Smith B D, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74( 11): 2913- 2921. DOI: 10.1158/0008-5472.CAN-14-0155.
    [12]
    Baralle F E, Giudice J. Alternative splicing as a regulator of development and tissue identity[J]. Nat Rev Mol Cell Biol, 2017, 18( 7): 437- 451. DOI: 10.1038/nrm.2017.27.
    [13]
    Bonnal S C, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer: Implications for care[J]. Nat Rev Clin Oncol, 2020, 17( 8): 457- 474. DOI: 10.1038/s41571-020-0350-x.
    [14]
    Zhang Y J, Qian J J, Gu C Y, et al. Alternative splicing and cancer: A systematic review[J]. Sig Transduct Target Ther, 2021, 6: 78. DOI: 10.1038/s41392-021-00486-7.
    [15]
    Zhang Y D, Wu J Y, Qin T J, et al. Comparison of the revised 4th(2016) and 5th(2022) editions of the World Health Organization classification of myelodysplastic neoplasms[J]. Leukemia, 2022, 36( 12): 2875- 2882. DOI: 10.1038/s41375-022-01718-7.
    [16]
    Yang Chenmeng, Wang Chunmei. Splicing factor SF3b6 promotes proliferation and migration of gastric cancer cells through MAPK signaling pathway[J]. Chin J Cancer Biother, 2021, 28( 3): 247- 253. DOI: 10.3872/j.issn.1007-385x.2021.03.005.

    杨晨萌, 王春梅. 剪接因子SF3b6通过MAPK信号通路促进胃癌细胞的增殖和迁移[J]. 中国肿瘤生物治疗杂志, 2021, 28( 3): 247- 253. DOI: 10.3872/j.issn.1007-385x.2021.03.005.
    [17]
    Yuan C X, Gao Y Y, Huang Y, et al. SF3B6 promotes the oncogenic phenotypes of MDA-MB-231 cells by extensively interacting with and regulating transcripts expression and alternative splicing[J]. Sci Rep, 2025, 15( 1): 39840. DOI: 10.1038/s41598-025-23477-y.
    [18]
    Kato K, Udagawa R, Hayashi Y, et al. SF3B14 is involved in the centrosome regulation through splicing of TUBGCP6 pre-mRNA[J]. Biochem Biophys Res Commun, 2022, 588: 133- 139. DOI: 10.1016/j.bbrc.2021.12.059.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (13) PDF downloads(0) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return